Business Context and Reporting Period
Company: Vaxcyte, Inc. (PCVX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Vaxcyte is a clinical-stage vaccine innovation company utilizing its proprietary XpressCF cell-free protein synthesis platform to develop high-fidelity vaccines against bacterial diseases. The company has no approved products and generates no product revenue. Its primary focus is the development of broad-spectrum pneumococcal conjugate vaccines (PCVs), specifically VAX-31 and VAX-24, for adult and pediatric populations.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(766.6) million | $(463.9) million | 65.2% increase |
| Operating Expenses | $923.7 million | $569.5 million | 62.2% increase |
| Research & Development (R&D) | $794.3 million | $476.6 million | 66.6% increase |
| General & Administrative (G&A) | $129.4 million | $92.9 million | 39.3% increase |
| Cash, Cash Equivalents & Investments | $2,442.6 million | $3,134.7 million | 22.1% decrease |
| Accumulated Deficit | $(2,154.9) million | $(1,388.3) million | N/A |
| Net Cash Used in Operating Activities | $(655.6) million | $(452.6) million | 44.9% increase |
Note: All figures in millions unless otherwise noted. The company reported no product revenue for the period.
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses rose by $317.7 million (66.6%) year-over-year, driven primarily by a $229.9 million increase in product manufacturing costs and a $17.3 million increase in clinical trial expenses. This reflects the advancement of VAX-31 and VAX-24 into pivotal Phase 3 trials and preparation for potential commercial launch.
- Foreign Currency Gains: Other income, net, increased by $41.7 million, largely due to a $42.7 million gain from unrealized and realized foreign currency fluctuations (weakening USD vs. Swiss Franc) related to manufacturing contracts with Lonza.
- Interest Income: Interest income increased by $9.7 million to $119.7 million, attributed to higher average cash balances and an increased duration of the investment portfolio.
- Capital Expenditures: Significant capital expenditures were incurred for manufacturing facility build-outs, with $217.1 million in Vaxcyte-owned facility build-out and equipment as of year-end 2025.
Guidance, Outlook, and Management Commentary
Clinical Pipeline Progress
- VAX-31 (Adults): Initiated the pivotal Phase 3 OPUS-1 trial in December 2025. Topline data is expected in Q4 2026. The FDA granted Breakthrough Therapy Designation (BTD) for IPD and pneumonia prevention. Two additional Phase 3 trials (OPUS-2 and OPUS-3) were initiated in early 2026.
- VAX-31 (Infants): Completed enrollment in the Phase 2 dose-finding study in January 2026. Topline data is expected in H1 2027. A Phase 3 program is planned pending these results.
- VAX-24 (Infants): Announced final positive Phase 2 data in November 2025, showing robust immune responses with little evidence of carrier suppression. This supports the strategy to advance higher doses in the VAX-31 infant program.
- Other Programs: VAX-A1 (Group A Strep) is expected to enter Phase 1 in 2026. VAX-GI (Shigella) advancement was paused in August 2025 to prioritize the PCV franchise.
Manufacturing and Commercialization
- Lonza Partnership: Entered into a new Development and Manufacturing Services Agreement in February 2026 (effective Jan 1, 2026) for commercial supply. A dedicated suite in Visp, Switzerland, is being built out.
- Thermo Fisher Partnership: Announced a long-term agreement in September 2025 for commercial fill-finish capacity in North Carolina, representing a commitment of up to $1 billion.
Risks and Contingencies
- Capital Needs: The company anticipates continuing to incur substantial net losses. While current cash reserves are sufficient for at least 12 months, substantial additional funding will be required to complete development and commercialization.
- Regulatory Uncertainty: Approval depends on meeting non-inferiority criteria in Phase 3 trials. The FDA may require additional studies or change approval standards.
- Manufacturing Reliance: The company relies entirely on third-party manufacturers (Lonza, Thermo Fisher). Disruptions or failures in these partnerships could delay timelines.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $2.44 billion cash position against the projected burn rate of ~$655 million annually, considering the high capital intensity of Phase 3 trials and commercial manufacturing build-outs.
- Phase 3 Trial Design: Confirm the specific non-inferiority margins and endpoints (OPA GMR) agreed upon with the FDA for the OPUS-1 trial, as these are critical for approval.
- Manufacturing Capacity: Assess the timeline for the Lonza facility build-out in Switzerland and the Thermo Fisher fill-finish capacity in North Carolina to ensure alignment with potential 2027/2028 commercial launch dates.
- Competitive Landscape: Monitor the progress of competitor PCVs (e.g., Pfizer's PCV25, Merck's PCV21, Sanofi/SK bioscience's 21-valent PCV) which may impact market share and pricing power.
- Foreign Currency Exposure: Evaluate the impact of USD/CHF exchange rate fluctuations on future operating costs, given the significant reliance on Swiss-based manufacturing.